<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6576">
  <stage>Registered</stage>
  <submitdate>24/06/2017</submitdate>
  <approvaldate>24/06/2017</approvaldate>
  <nctid>NCT03202992</nctid>
  <trial_identification>
    <studytitle>Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection</studytitle>
    <scientifictitle>Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Topical ABI-1968 in Subjects With Anal High-Grade Squamous Intraepithelial Lesions (aHSIL)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ABI-1968-201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HSIL, High-Grade Squamous Intraepithelial Lesions</healthcondition>
    <healthcondition>Human Papilloma Virus Infection</healthcondition>
    <healthcondition>HIV Infection</healthcondition>
    <healthcondition>Anal Cancer</healthcondition>
    <healthcondition>Anus Neoplasms</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Sexually transmitted infections</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Anal</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABI-1968

Experimental: Dose 1 -Single Ascending Dose (SAD) - SAD Dose Level 1 of ABI-1968 topical cream applied on Day 1 of the study

Experimental: Dose 2 -Single Ascending Dose (SAD) - SAD Dose Level 2 of ABI-1968 topical cream applied on Day 1 of the study

Experimental: Dose 3 -Single Ascending Dose(SAD) - SAD Dose Level 3 of ABI-1968 topical cream applied on Day 1 of the study

Experimental: Dose 4 -Single Ascending Dose(SAD) - SAD Dose Level 4 of ABI-1968 topical cream applied on Day 1 of the study

Experimental: Dose 5 -Single Ascending Dose(SAD) - SAD Dose Level 5 of ABI-1968 topical cream applied on Day 1 of the study

Experimental: Dose 1 - Multiple Ascending Dose(MAD) - MAD Dose Level 1 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29

Experimental: Dose 2 -Multiple Ascending Dose(MAD) - MAD Dose Level 2 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29

Experimental: Dose 3 -Multiple Ascending Dose(MAD) - MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29

Experimental: Multiple Ascending Dose (MAD) Cohort Expansion - MAD Cohort Expansion of ABI-1968 applied at Day 1, Day 8, Day 15, Day 22 and Day 29


Treatment: drugs: ABI-1968
Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of aHSIL - Number of participants with Adverse Events related to treatment</outcome>
      <timepoint>SAD portion is 29 days/MAD portion is 84 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Systemic exposure to ABI-1968 Topical Cream following topical application to the anal canal. - Plasma concentrations of ABI-1968 over time</outcome>
      <timepoint>SAD portion is 29 days/MAD portion is 84 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Histopathology of areas with biopsy-proven disease following single and multiple doses of ABI-1968 Topical Cream. - Number of subjects with complete and or partial regression of aHSIL by High Resolution Anoscopy (HRA) and histopathology</outcome>
      <timepoint>SAD portion is 29 days/MAD portion is 84 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Female or male subjects, at least 27 years old.

          2. Confirmed diagnosis of intra-anal HSIL at least 3 months prior to screening and
             confirmed by histopathology (with p16 positive staining)

          3. Intra-anal HSIL are visible and evaluable by HRA at the time of screening, and no
             lesion(s) is suspicious for invasive cancer.

          4. For HIV-positive subjects, CD4 count must be at least 200/mm3 with undetectable (&lt;50
             copies/mL) viral load within the 3 months prior to enrollment. Subjects must be on a
             stable regimen of antiretroviral drugs for the 3 months prior to enrollment.</inclusivecriteria>
    <inclusiveminage>27</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Women who are pregnant, plan to become pregnant in the next 3 months, or lactating
             females.

          2. Received topical treatment or ablative procedures for aHSIL in the 6 months prior to
             enrolment.

          3. History of cancer, including anal cancer (with the exception of basal cell or squamous
             cell carcinoma of the skin), or currently undergoing treatment for any skin cancer.

          4. History of genital herpes with &gt; 3 outbreaks per year.

          5. Plan to have excision or ablation of the lesion(s) within 3 months of enrolment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Other</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>11/08/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>57</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>Darlinghurs</recruitmentstate>
    <hospital>Research Center - Sydney</hospital>
    <postcode>2010 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Antiva Biosciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study evaluates the use of ABI-1968, a topical cream, in the treatment of anal
      precancerous lesions in adults with and without human immunodeficiency virus (HIV) infection.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03202992</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Operations</name>
      <address>Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may use the contacts provided below. For general i</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Clinical Operations</name>
      <address />
      <phone>650-822-1400</phone>
      <fax />
      <email>Clinical@antivabio.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>